×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
Yahoo Finance
Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H'24 Global Phase 2 HCV Study On...
4 days ago
Atea: Nature and Divinity in Polynesia
The Metropolitan Museum of Art
Atea: Nature and Divinity in Polynesia focuses on an array of artistic creations that illuminate how Polynesians traditionally understood their relationship...
3 weeks ago
Atea Pharmaceuticals, Inc. Expected to Post Q1 2025 Earnings of ($0.60) Per Share (NASDAQ:AVIR)
Defense World
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR – Free Report) – Research analysts at William Blair issued their Q1 2025 EPS estimates for shares of...
1 day ago
Atea Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation (NASDAQ:AVIR)
Seeking Alpha
The following slide deck was published by Atea Pharmaceuticals, Inc.
4 days ago
AVIR Stock Earnings: Atea Pharmaceuticals Misses EPS for Q1 2024
MSN
AVIR stock results show that Atea Pharmaceuticals missed analyst estimates for earnings per share the first quarter of 2024.More From InvestorPlace The #1...
4 days ago
Earnings call: Atea Pharmaceuticals reports progress in COVID-19 trial
Investing.com
Atea Pharmaceuticals, a biopharmaceutical company focused on developing therapeutics for viral diseases, has announced notable advancements...
4 days ago
Brokers Set Expectations for Atea Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:AVIR)
MarketBeat
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR - Free Report) - Equities research analysts at William Blair issued their Q1 2025 earnings estimates...
2 days ago
Atea Pharmaceuticals reports Q1 EPS (75c), consensus (61c) - TipRanks.com
Tipranks
Cash, Cash Equivalents and Marketable Securities: $541.5M at March 31, 2024 compared to $578.1M at December 31 .
4 days ago
Atea Pharmaceuticals to Host First Quarter 2024 Financial Results Conference Call on May 14, 2024
GlobeNewswire
BOSTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical...
2 weeks ago
Atea (OB:ATEA) jumps 4.3% this week, though earnings growth is still tracking behind five-year shareholder returns
Simply Wall Street
Stock pickers are generally looking for stocks that will outperform the broader market. Buying under-rated businesses...
6 days ago